Clinical Trial Update: DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact [Phase 2]

View source ↗

Summary

Phase 2 trial investigating intravitreal aflibercept (EYLEA) for diabetic macular edema; results from the study have been completed and posted (2014).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED | Results posted: 2014-09-09